House _____ **Amendment NO.**____

Offered By

_____ _____

AMEND House Committee Substitute for House Bill Nos. 1717 & 1643, Page 6, Section 191.480, Line 68, by inserting after all of said section and line the following:

"191.647. 1. As used in this section, the following terms mean:

(1) "DEHP", di(2-ethylhexyl) phthalate;

(2) "Intentionally added DEHP", DEHP that a manufacturer has intentionally added to a product and that has a functional or technical effect on the product;

(3) "Intravenous solution container", a container used to house medicine, fluid, or nutrition therapy that is intravenously delivered to a patient in a hospital, outpatient facility, or other health care facility;

(4) "Intravenous tubing", tubing used to intravenously administer fluids, medication, or nutrients directly to an adult, child, or infant;

(5) "Ortho-phthalate", a class of chemicals that are esters of ortho-phthalic acid, including DEHP or any of the following:

(a) Benzyl butyl phthalate (BBP);

(b) Dibutyl phthalate (DBP);

(c) Dicyclohexyl phthalate (DCHP);

(d) Diethyl phthalate (DEP);

(e) Diisobutyl phthalate (DIBP);

(f) Diisodecyl phthalate (DIDP);

(g) Diisononyl phthalate (DINP);

(h) Di-n-hexyl phthalate (DnHP);

(i) Di-n-octyl phthalate (DNOP);

(j) Di-n-pentyl phthalate (DnPP); or

(k) Diisoheptyl phthalate (DIHP);

(6) "Unintentionally added DEHP", DEHP in an intravenous solution container or intravenous tubing product that is not used for functional or technical effect on the product.

2. Beginning January 1, 2030, a person or entity shall not sell or distribute into commerce in this state intravenous solution containers made with intentionally added DEHP.

Action Taken_____ Date _____

3. Beginning January 1, 2035, a person or entity shall not manufacture, sell, or distribute into commerce in this state intravenous tubing made with intentionally added DEHP.

4. A person or entity subject to the prohibitions in this section shall not replace DEHP with another ortho-phthalate in a new or revised medical device.

5. An intravenous solution container or intravenous tubing product shall not have unintentionally added DEHP present at a quantity at or above one-tenth of one percent weight per weight.

6. The following items, as described in Title 21 of the Code of Federal Regulations, shall be exempt from the requirements of this section:

(1) Human blood collection and storage bags; and

(2) Apheresis and cell therapy blood kits and bags, including integral tubing.

7. The date of January 1, 2030, by which compliance is required for a person or entity under subsection 2 of this section shall be extended to January 1, 2032, if all of the following conditions are met:

(1) The need for an extension is due to pending United States Food and Drug Administration approval for the DEHP-free intravenous solution container or due to the manufacturer not having adequate equipment to manufacture the DEHP-free intravenous solution container;

(2) The person or entity notified its Missouri customers, before October 1, 2026, that it has commenced development of the DEHP-free intravenous solution container to meet the requirements of this section; and

(3) The person or entity provides notice to its customers and posts to its official internet website, before January 1, 2028, that it will not meet the deadline imposed under subsection 2 of this section."; and

Further amend said bill by amending the title, enacting clause, and intersectional references accordingly.